TherapeuticsMD, Inc.

Good morning, ladies and gentlemen. Thank you for joining us for the TherapeuticsMD second quarter 2021 financial results conference call. Following prepared remarks from the company, we will open the call for questions. I would now like to turn the call over to Investor Relations for TherapeuticsMD, Lisa Wilson. Lisa?

Thank you, Christy. Good morning, everyone, and thank you for joining us today to discuss our second quarter financial results and business updates. This morning, TherapeuticsMD issued a press release announcing our second quarter financial results. The press release is available on the company's website, therapeuticsmd.com, in the Investors and Media section. On today's call from TherapeuticsMD are Chief Executive Officer Rob Fenizio, Chief Financial Officer James Durecka, Chief Commercial Officer Don Halkoff, and Chief Strategy and Performance Officer Mitchell Crassens. I would like to remind everyone that certain statements made during this conference call may be forward-looking statements. Such forward-looking statements are based upon current expectations and there can be no assurance that the results contemplated in these statements will be realized. Actual results may differ materially from such statements due to a number of factors and risks, some of which are identified in our press release and our annual, quarterly, and other reports filed with the SEC. These forward-looking statements are based on information available to TherapeuticsMD today, and the company assumes no obligation to update statements as circumstances change. An audio recording and webcast replay for today's conference call will also be available online in the Investors and Media section of the company's website. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on August 4, 2021. With that, I'll turn the call over to Therapeutics MD's CEO, Rob Fenicio.

Good morning, and thank you for joining our Q2 call. We are pleased with our steady progress in line with our expectations. Our sales force is benefiting from improved access to providers, which while not back to pre-pandemic levels, has opened up. In addition, the efforts we have made during the quarter to create a more streamlined and improved online patient experience are gaining traction. With Upscript, our newest telemedicine relationship now live, we expect to see continued growth with or without COVID-19 through our online channels. Finally, we have strong coverage for all of our products in the marketplace, and we expect continued improvement in insurance coverage throughout Q3 and Q4. As shown in slide three, overall, our revenue increased by 17% in the second quarter of this year compared with the first quarter. Our overall volumes and net revenues were healthy, and VitaCare Prescription Services is also experiencing growth. We recently signed our third VitaCare customer contract and have a strong pipeline of over 30 potential customers. In addition, we continue to evaluate the investment into VitaCare, including potentially selling a minority stake in VitaCare, which would provide a non-dilutive source of capital for our company. We're building a solid foundation for VitaCare to become a freestanding entity in this high-growth sector. Before I turn the call over to James, I'd like to welcome Hugh O'Dowd, who is stepping into the position of President of TherapeuticsMD, which John Milligan vacated to take the position of Chief Executive Officer of VitaCare Prescription Services earlier this year. Hugh was previously the CEO and President of Neon Therapeutics. Hugh joined Neon from Novartis. where he spent more than 20 years in a variety of leadership roles, including chief commercial officer and head of global strategy. I'll now turn the call over to James to discuss our financials in more detail.